Aims:

• Demonstrate which type of dendritic cells activate immunity and identify what happens in the body that stops them from working against ovarian cancer.
• Identify which molecules on the surface of dendritic cells should be targeted with a vaccine to activate the immune system most effectively against ovarian cancer.

Approach:

With OCRF funding researchers will:

• Observe the way dendritic cells function in ovarian cancer samples to determine why they don’t kick start the immune system to respond against ovarian cancer.
• Compare the differences in dendritic cell function between healthy donors and ovarian cancer patient samples.
• Identify molecules on the surface of dendritic cells that could best activate the immune system against ovarian cancer and design a vaccine to target them.
• Test the use of a dendritic cell-based vaccine on patient samples.

Ambition and outcomes:

By demonstrating exactly how and why dendritic cells function differently when faced with ovarian cancer, Professor Radford’s team could uncover the foundations of a targeted vaccine.

The project could also assist in avoiding disease recurrence through a vaccine treatment that prompts an individual’s immune system to recognise their specific ovarian cancer type.

Immunotherapies have shown promise in treating other cancers. With most ovarian cancer cases currently diagnosed in later stages, this project could provide a live-saving treatment option for future patients.

Professor Radford's project will commence in July 2024.

This article has been reviewed and approved by Professor Kristen Radford.